Sclerostin: Another vascular calcification inhibitor?

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 8, 2013, Pages 3221-3228

  Claes, Kathleen J ^a   Viaene, Liesbeth ^a   Heye, Sam ^a   Meijers, Björn ^a   D'Haese, Patrick ^b   Evenepoel, Pieter ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; C REACTIVE PROTEIN; SCLEROSTIN; UNCLASSIFIED DRUG; VASCULAR CALCIFICATION INHIBITOR;

ADULT; AGE; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AORTA DISEASE; AORTIC CALCIFICATION; ARTICLE; BLOOD VESSEL CALCIFICATION; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIALYSIS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENDER; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SCORING SYSTEM; X RAY;

ADULT; AGED; AORTIC DISEASES; BONE MORPHOGENETIC PROTEINS; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC MARKERS; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; VASCULAR CALCIFICATION; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84881527492     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1521     Document Type: Article

References (41)

1. Budoff MJ, Rader DJ, Reilly MP, et al. Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis. 2011;58:519-526.
2. García-Canton C, Bosch E, Ramírez A, et al. Vascular calcification and 25-hydroxy vitamin D levels in non-dialysis patients with chronic kidney disease stages 4 and 5. Nephrol Dial Transplant. 2011;26:2250-2256.
3. Petchey WG, Hawley CM, Johnson DW, Haluska BA, Watkins TW, Isbel NM. Multimodality vascular imaging in CKD: divergence of risk between measured parameters. Nephrol Dial Transplant. 2012; 27:1004-1012.
4. Matias PJ, Ferreira C, Jorge C, et al. 25-Hydroxy vitamin D3, arterial calcifications and cardiovascular risk markers in haemodialysis patients. Nephrol Dial Transplant. 2009;24:611-618.
5. Mazzaferro S, Pasquali M, Taggi F, et al. Progression of coronary artery calcification in renal transplantation and the role of secondary hyperparathyroidism and inflammation. Clin J Am Soc Nephrol. 2009;4:685-690.
6. Moe SM, Drüeke T, Lameire N, Eknoyan G. Chronic kidney disease-mineral-bone disorder: a new paradigm. Adv Chronic Kidney Dis. 2007;14:3-12.
7. Nitta K, Akiba T, Suzuki K, et al. Assessment of coronary artery calcification in hemodialysis patients using multi-detector spiral CT scan. Hypertens Res. 2004;27:527-533.
8. Neven E, Persy V, Dauwe S, De Schutter T, De Broe ME, D'Haese PC. Chondrocyte rather than osteoblast conversion of vascular cells underlies medial calcification in uremic rats. Arterioscler Thromb Vasc Biol. 2010;30:1741-1750.
9. Speer MY, Yang HY, Brabb T, et al. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res. 2009;104:733-741.
10. Shroff RC, McNair R, Skepper JN, et al. Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. J Am Soc Nephrol. 2010;21:103-112.
11. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol. 2004;15:2959-2964.
12. Cannata-Andia JB, Roman-Garcia P, Hruska K. The connections between vascular calcification and bone health. Nephrol Dial Transplant. 2011;26:3429-3436.
13. Baron R, Rawadi G. Wnt signaling and the regulation of bone mass. Curr Osteoporos Rep. 2007;5:73-80.
14. Caira FC, Stock SR, Gleason TG, et al. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol. 2006;47:1707-1712.
15. Shao J, Aly Z, Lai CF, et al. Vascular Bmp Msx2 Wnt signaling and oxidative stress in arterial calcification. Ann NY Acad Sci. 2007; 1117:40-50.
16. Zhu D, Mackenzie NC, Millan JL, Farquharson C, MacRae VE. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One. 2011;6: e19595.
17. Román-Garcia P, Carillo-López N, Fernández- Martín JL, Naves-Díaz M, Ruiz-Torres MP, Cannata-Andía JB. High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression. Bone. 2010;46:121-128.
18. Bouillon R, Coopmans W, Degroote DE, Radoux D, Eliard PH. Immunoradiometric assay of parathyrin with polyclonal and monoclonal region-specific antibodies. Clin Chem. 1990;36:271-276.
19. Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PW. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis. 1997;132:245-250.
20. Lombardi G, Lanteri P, Colombini A, Mariotti M, Banfi G. Sclerostin concentrations in athletes: role of load and gender. J Biol Regul Homeost Agents. 2012;26:157-163.
21. Cejka D, Jäger-Lansky A, Kieweg H, et al. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant. 2012;27:226-230.
22. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305.
23. Kular J, Tickner J, Chim SM, Xu J. An overview of the regulation of bone remodelling at the cellular level. Clin Biochem. 2012;45:863-873.
24. Moester MJ, Papapoulos SE, Löwik CW, van Bezooijen RL. Sclerostin: current knowledge and future perspectives. Calcif Tissue Int. 2010;87:99-107.
25. Beighton PH, Hamersma H, BrunkowME.SOST-related sclerosing bone dysplasias. In: Pagon RA, AdamMP, Bird TD, Dolan CR, Fong CT, Stephens K, eds. GeneReviews. Seattle, WA: University of Washington, Seattle; 1993-2013.
26. Amrein K, Amrein S, Drexler C, et al. Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab. 2012; 97:148-154.
27. Ardawi MS, Al-Kadi HA, Rouzi AA, Qari MH. Determinants of serum sclerostin in healthy pre-and postmenopausal women. J Bone Miner Res. 2011;26:2812-2822.
28. Mödder UI, Hoey KA, Amin S, et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. 2011;26:373-379.
29. Bonnet N, Standley KN, Bianchi EN, et al. The matricellular protein periostin is required for sost inhibition and the anabolic response to mechanical loading and physical activity. J Biol Chem. 2009;284: 35939-35950.
30. Gaudio A, Pennisi P, Bratengeier C, et al. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab. 2010;95:2248-2253.
31. Chow JT, Khosla S, Melton LJ 3rd, Atkinson EJ, Camp JJ, Kearns AE. Abdominal aortic calcification, BMD, and bone microstructure: a population-based study. J Bone Miner Res. 2008;23:1601-1612.
32. Drake MT, Srinivasan B, Mödder UI, et al. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab. 2010;95:5056-5062.
33. Koos R, Mahnken A, Marx N, Brandenburg V. Sclerostin as potential novel biomarker for aortic valve calcification. J Am Coll Cardiol. 2012;59:E2007.
34. Ardawi MS, Al-Sibiany AM, Bakhsh TM, Rouzi AA, Qari MH. Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study. Osteoporos Int. 2012;23:1789-1797.
35. Kramer I, Keller H, Leupin O, Kneissel M. Does osteocytic SOST suppression mediate PTH bone anabolism? Trends Endocrinol Metab. 2010;21:237-244.
36. Disthabanchong S, Hassan H, McConkey CL, Martin KJ, Gonzalez EA. Regulation of PTH1 receptor expression by uremic ultrafiltrate in UMR 106-01 osteoblast-like cells. Kidney Int. 2004;65:897-903.
37. Viaene L, Behets GJ, Claes KJ, et al. Sclerostin: another bone-related protein related to all-cause mortality in hemodialysis [published online ahead of print April 19, 2013]? Nephrol Dial Transplant. doi: 10.1093/ndt/gft039.
38. De Schutter TM, Neven E, Persy VP, et al. Vascular calcification is associated with cortical bone loss in chronic renal failure rats with and without ovariectomy: the calcification paradox. Am J Nephrol. 2011;34:356-366.
39. Wijenayaka AR, Kogawa M, Lim HP, et al. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One. 2011;6:e25900.
40. Cejka D, Herberth J, Branscum AJ, et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol. 2011; 6:877-882.
41. Thambiah S, Roplekar R, Manghat P, et al. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int. 2012;90:473-480.